Alterity CEO presents at MST Financial Biotech & Healthcare Webinar Series
Alterity Therapeutics CEO Dr David Stamler recently joined the MST Financial Biotech & Healthcare Webinar Series to give an update on the Company’s progress developing ATH434 as a potential disease-modifying treatment for Multiple System Atrophy (MSA). In the presentation, Dr Stamler discussed the ATH434-201 Phase 2 trial results and how the data informed the next stage of clinical development, as well as the registrational Phase 3 path forward. Watch the replay below, which starts with Alterity's presentation at 33:55.